Best Practices for Treating HCM: Global ViewsPremiere Date: Wednesday, April 20, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, April 20, 2023
|Martin S. Maron, MD (Moderator)
Director, Hypertrophic Cardiomyopathy Center
Co-Director, Cardiac CT and MRI
Tufts University School of Medicine
|Iacopo Olivotto, MD
Head, Cardiomyopathy Unit
Careggi University Hospital
University of Florence
Hypertrophic cardiomyopathy (HCM) can be a chronic, progressive condition in which patients experience symptoms of dyspnea, dizziness, and fatigue as well as serious complications such as heart failure, arrhythmias, stroke, and sudden cardiac death. HCM is a masquerading disease and is easily confused with other conditions. Because there are many different symptomatic manifestations of HCM, clinicians are not always up to date with evidence-based treatment recommendations, missing opportunities to provide relief to patients with HCM. Practice guidelines for HCM released in December 2020 by the AHA/ACC provide further detail on when to use available treatment options. Clinicians need to stay current on the latest recommendations to prepare to treat or refer patients with HCM to a specialist.
Join Drs. Maron and Olivotto in this 2nd installment of a 3-part CMEO Snack series on HCM as they identify strategies for clinicians to better implement global and country-specific guideline recommendations to improve care for patients with HCM.
At the end of this CE activity, participants should be able to:
- Implement global and country-specific practice guideline recommendations to improve care for patients with HCM.
Supported by an educational grant from Bristol Myers Squibb.
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Maron reports the following financial relationships:
Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee)
Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Olivotto reports the following financial relationships:
Advisory Board: Amicus Therapeutics, Inc.; Bristol Myers Squibb; Cytokinetics; and Tenaya Therapeutics
Consultant: Amicus Therapeutics, Inc.; Bayer; Bristol Myers Squibb; Cytokinetics; Genzyme; and Tenaya Therapeutics
Grants/Research Support: Amicus Therapeutics, Inc.; Boston Scientific Corporation; Bristol Myers Squibb; Cytokinetics; Menarini International; and Tenaya Therapeutics
Speakers Bureau: Amicus Therapeutics, Inc.; Boston Scientific Corporation; Bristol Myers Squibb; and Novartis
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).